MAP3K7 and glioblastoma: Further studies are required to assess the therapeutic effect of TAK1 inhibition in GBM and other cancer models in vivo alone or in combination with other cytotoxic or immune-modulatory agents to target the main bulk of proliferating tumor cells and potentiate the treatment effects on overall tumor cell viability and growth.